The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Paliperidone Janssen-Cilag International 50 mg prolonged-release suspension for injection



Janssen Pharmaceutica NVEU/1/20/1453/002

Main Information

Trade NamePaliperidone Janssen-Cilag International 50 mg prolonged-release suspension for injection
Active SubstancesPaliperidone palmitate
Dosage FormProlonged-release suspension for injection
Licence HolderJanssen Pharmaceutica NV
Licence NumberEU/1/20/1453/002

Group Information

ATC CodeN05AX13 paliperidone

Status

License statusAuthorised
Licence Issued18/06/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Generics Information

Interchangeable List CodeIC0130-023-064
Interchangeable List DocumentPDF of Interchangeable List
« Back